Loading
Mathematical Biology Tumor Growth · Journal article
Frontiers in Pharmacology · August 12, 2026
A consensus or society position rather than new primary data.
This is a narrative review of spatial pharmacology as a framework for understanding anti-cancer immunomodulator interactions with tumors and their microenvironment at single-cell resolution. The article synthesizes conceptual foundations and emerging technologies (scRNA-seq, spatial transcriptomics, AI-driven multi-omics) without reporting original empirical findings, outcome data, or systematic evidence synthesis. It describes spatial pharmacology's potential to address intratumoral heterogeneity and personalize cancer immunotherapy, but provides no quantified efficacy, safety, or comparative effectiveness data.
Journal article. Patients with cancer receiving anti-cancer immunomodulators, with emphasis on metastatic renal cell carcinoma and triple-negative breast cancer..
Spatial pharmacology integrates single-cell analysis, signaling dynamics, and multimodal approaches to address limitations of traditional therapies by accounting for intratumoral heterogeneity and immune cell spatial organization. Clinical applications include optimizing combinatorial regimens in metastatic renal cell carcinoma and predicting immunotherapy response in triple-negative breast cancer. Key diagnostic advancements cited include scRNA-seq for mapping drug target pathway activation and imaging techniques for visualizing signaling dynamics.
No original efficacy or safety data reported; review synthesizes literature without specifying search strategy or inclusion criteria. Spatial pharmacology integrates single-cell analysis, signaling dynamics, and multimodal approaches to address limitations of traditional therapies by accounting for intratumoral heterogeneity and immune cell spatial organization.
This review frames spatial pharmacology as a conceptual and technological approach to personalized cancer immunotherapy, but does not provide outcome data, efficacy estimates, or clinical decision-making evidence that would inform direct practice changes. Clinicians should recognize this as a state-of-the-art synthesis of emerging methodologies rather than validated clinical guidance.
A comprehensive narrative review synthesizing theoretical foundations, techniques, and clinical applications of spatial pharmacology in cancer immunotherapy without reporting original empirical results or outcomes data.
This review frames spatial pharmacology as a conceptual and technological approach to personalized cancer immunotherapy, but does not provide outcome data, efficacy estimates, or clinical decision-making evidence that would inform direct practice changes. Clinicians should recognize this as a state-of-the-art synthesis of emerging methodologies rather than validated clinical guidance.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The field of spatial pharmacology has emerged as a critical framework for understanding the complex interactions between anti-cancer immunomodulators, tumor cells, and the tumor microenvironment (TME) at single-cell resolution. This review synthesizes the theoretical foundations, historical evolution, clinical applications, diagnostic techniques, therapeutic strategies, and future directions of spatial pharmacology in cancer immunotherapy. By integrating single-cell analysis, signaling dynamics, and multimodal approaches, spatial pharmacology addresses the limitations of traditional “one-size-fits-all” therapies by accounting for intratumoral heterogeneity, drug target accessibility, and immune cell spatial organization. Key advancements include single-cell RNA sequencing (scRNA-seq) for mapping drug target pathway activation, imaging techniques for visualizing signaling dynamics, and multimodal diagnostics for personalized treatment design. Clinical applications range from optimizing combinatorial regimens in metastatic renal cell carcinoma to predicting immunotherapy response in triple-negative breast cancer. Despite challenges such as overcoming drug resistance and enhancing target accessibility, emerging technologies like spatial transcriptomics and artificial intelligence (AI)-driven multi-omics integration promise to revolutionize precision oncology. This review highlights how spatial pharmacology is transforming cancer immunotherapy by enabling tailored interventions that account for the spatial and temporal complexity of tumor-immune interactions.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.